|
Lymphomatoid Papulosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of the study was to describe 13 cases of a unique PLEVA variant characterized in the conspicuous CD30 component and thus mimicking lymphomatoid papulosis (LyP), a condition currently classified in the spectrum of CD30 lymphoproliferative disorders.
|
22472952 |
2012 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lymphomatoid papulosis (LyP) is defined as a chronic recurrent skin disease characterized by waxing and waning papules and nodules with histologic features of a CD30-positive T-cell lymphoma.
|
22688398 |
2012 |
|
Lymphomatoid Papulosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
They include lymphomatoid papulosis and cutaneous anaplastic large-cell lymphoma which are characterized by the common expression of the CD30 antigen, but different clinical, histological and molecular features.
|
23149700 |
2012 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Current pathologic criteria cannot reliably distinguish cutaneous anaplastic large cell lymphoma from other CD30-positive T-cell lymphoproliferative disorders (lymphomatoid papulosis, systemic anaplastic large cell lymphoma with skin involvement, and transformed mycosis fungoides).
|
21169992 |
2011 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Primary cutaneous ALCL (C-ALCL) is part of the spectrum of CD30+ lymphoproliferative diseases of the skin including lymphomatoid papulosis.
|
20669794 |
2010 |
|
Lymphomatoid Papulosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lymphomatoid papulosis (LyP) is a recurrent, self-healing eruption belonging to the spectrum of cutaneous CD30+lymphoproliferative disorders.
|
20661014 |
2010 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report a case of CD30 (Ki-1)-positive LyP which developed recurrently and was confined to the periorbital areas.
|
19335692 |
2009 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Twenty-one of 148 (14.2%) patients with CTCLs were positive for HHV7 DNA: nine of 39 (23.1%) SS, six of 14 (42.9%) CD30+ CTCLs and six of 24 (25.0%) LyP, and HHV7 DNA was negative in all 71 patients with MF.
|
18782321 |
2008 |
|
Lymphomatoid Papulosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Studies of genetic variants of the CD30 promoter showed distinct microsatellite alleles associated with development of LyP and lymphoma progression.
|
17387297 |
2007 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In situ hybridization studies showed positivity of the neoplastic cells for EBER in two of 16 cases of CD30+ ALCL and in none of the cases of LyP.
|
17076712 |
2006 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Skin biopsy revealed proliferation of CD30(+) T cells consistent with lymphomatoid papulosis (LyP), whereas molecular analysis of peripheral blood mononuclear cells demonstrated the presence of the FIP1L1/PDGFRA fusion gene.
|
16965435 |
2006 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD30+ cutaneous lymphoproliferative disorders include lymphomatoid papulosis (LyP) and anaplastic large cell lymphoma (ALCL).
|
16412208 |
2006 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we determined that two allelic forms of the CD30 promoter microsatellite repressive element, designated 30M377 and 30M362, are associated with the development of lymphomatoid papulosis and CD30+ lymphomas in lymphomatoid papulosis patients, respectively.
|
15894695 |
2005 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data demonstrate that expression of c-kit receptor is exceedingly rare among CD30+ lymphomas and lymphomatoid papulosis, suggesting that c-kit receptor is unlikely to be an appropriate target for therapeutic options such as imatinib in patients with these tumors.
|
15105813 |
2004 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Purportedly, CD30 is useful in the differential diagnosis between insect bites and lymphomatoid papulosis.
|
12826883 |
2003 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
LHGDN |
To definitively clarify whether the large atypical CD30(+) cells in LyP without associated lymphoma all belong to the same clone or represent individually rearranged T cells, we analyzed the T-cell receptor-gamma rearrangements of single CD30+ as well as of single CD30- cells isolated from 14 LyP lesions of 11 patients.
|
12091351 |
2002 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
While lesions of lymphomatoid papulosis are definitionally positive for CD30, their ability to express CD56 has not been formally studied.
|
12150138 |
2002 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
To definitively clarify whether the large atypical CD30(+) cells in LyP without associated lymphoma all belong to the same clone or represent individually rearranged T cells, we analyzed the T-cell receptor-gamma rearrangements of single CD30+ as well as of single CD30- cells isolated from 14 LyP lesions of 11 patients.
|
12091351 |
2002 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lymphomatoid papulosis (LyP) is a chronic, recurrent lymphoproliferative disorder of the skin that belongs to the group of primary cutaneous CD30-positive T-cell lymphomas.
|
11168749 |
2001 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our objective is to understand the mechanism of progression of lymphomatoid papulosis (LyP) to CD30+ systemic lymphoma.
|
11594583 |
2001 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical stains for CD8, CD30, CD79 and CLA may be valuable tools in the differential diagnosis between PLEVA and LyP.
|
11553311 |
2001 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lymphomatoid papulosis (LyP) is defined as a recurrent self-healing papulonodular eruption with the histological features of a (CD30+) cutaneous T-cell lymphoma.
|
11531801 |
2001 |
|
Lymphomatoid Papulosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The purpose of this article is to review the pathologic and clinical spectrum of ALCL, including the borderline with Hodgkin's disease and lymphomatoid papulosis and to discuss the use of the t(2;5) in better defining a more specific molecular pathologic entity within this group of diseases with CD30 expression.
|
9894470 |
1999 |
|
Lymphomatoid Papulosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nine of 17 cases showed the characteristic clinical and histological features as well as clinical behavior of well defined types of CTCL, such as mycosis fungoides (2 cases), pagetoid reticulosis (2 cases), lymphomatoid papulosis (2 cases), and CD30+ large T cell lymphoma (2 cases), all of which usually express a CD4+ T cell phenotype, and 1 case of subcutaneous panniculitis-like T cell lymphoma.
|
10433941 |
1999 |
|
Lymphomatoid Papulosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aggregate results of these studies indicate that the t(2;5) translocation or other somatic mutations resulting in inappropriate expression of ALK are involved rarely if at all in the pathogenesis of Hodgkin's disease, but may be present in about 10% of cases of lymphomatoid papulosis and 20% of cases of CD30+ primary cutaneous large cell lymphoma.
|
9638979 |
1998 |